Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05570435
Other study ID # 21.16.NR
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 16, 2022
Est. completion date March 14, 2023

Study information

Verified date June 2023
Source Société des Produits Nestlé (SPN)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a monocentric, randomized controlled, open-label, 2x2 cross-over study. The main objective of the study is to Evaluate the efficacy of Nestle YIYANG TangLv milk powder in lowering the Post Prandial Glucose Response (PPGR) of a high carbohydrate meal when consumed with the meal.


Description:

This is an acute, monocentric, open label, randomized, 2-arm, cross-over, clinical trial in 30 subjects of Chinese Han ethnicity. Subjects will receive the two different interventions in a randomized order. This study will assess the efficacy of the investigational product after a single consumption. Day before (V1 and V3) the intervention visits (V2 and V4) the subjects will be admitted at the investigational site for an overnight stay where they will consume a standardized dinner. V2 and V3 will be followed by a wash-out period of 3 days. The two arms are: Arm 1: skimmed milk (control) Arm 2: Nestle YIYANG TangLv milk powder


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date March 14, 2023
Est. primary completion date March 14, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: 1. Willing and able to sign written informed consent prior to trial entry 2. Deemed able to comply with study protocol for 2-3 weeks 3. Male or female aged 45-75 years (inclusive 45 and 75) 4. HbA1c test results < 6.5% at Visit 1 (Admission 1) 5. Waist circumference =90 cm in males and = 85 cm in females 6. Chinese Han ethnic group 7. BMI >18.5 and <28 kg/m2 Exclusion Criteria: 1. Pre-existing chronic medical or psychiatric conditions, as diagnosed by the treating physician (psychiatric illness, asthma or chronic lung disease requiring long term medications or oxygen, diabetes mellitus, chronic infective disease, including tuberculosis, hepatitis B and C, and HIV) 2. Significant medical or surgical event in the past 3 months potentially interfering with study procedures and assessments 3. Known food allergy in particular cow's milk protein allergy (CMPA), lactose and /or soy intolerance or known hypersensitivity/intolerance to any other ingredients in the study product 4. Known substance abuse or alcohol user exceeds following intake, alcohol intake > 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer 5. Consumption of tobacco products, smoking or chewing tobacco 6. History of significant organ dysfunction or disease 7. Subjects with refractory hypertension, and patients with hypertension who are taking antihypertensive drugs (beta-blockers, thiazide diuretics, etc.) that may affect blood glucose metabolism 8. Females currently on hormonal therapy including post-menopausal hormone replacement therapy (PRT) or have been on PRT treatment in the past two months before study participation 9. Known autoimmune and/or genetic disease 10. Known chronic diarrhea or gastrointestinal discomfort 11. Known endocrine and metabolic diseases under drug treatment (e.g., pituitary tumors, thyrotoxicosis due to various causes, Cushing's syndrome etc.) 12. Subjects on systemic corticosteroids, glucocorticoids, or cyclosporine A 13. Recent blood donation (<8 weeks) 14. Pregnant or lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood collection
Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Société des Produits Nestlé (SPN) Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other additional endpoints slopes derived from PPGR additional endpoints slopes derived from PPGR 0, 15, 30 min or 1 hour, 2 hours, 3 hours
Primary 3h-iAUC of PPGR Incremental area under the curve (3h-iAUC0-3h) of the post-prandial plasma glucose concentration (PPGR) 3 hours
Secondary iAUC of PPGR Incremental area under the curve of PPGR (Postprandial Glucose Response) 1hour, 2 hours
Secondary Tmax of PPGR Tmax(the time when Cmax is achieved) of PPGR (Postprandial Glucose Response) 3 hours
Secondary Cmax of PPGR Cmax(maximal value of measured timepoints) of PPGR (Postprandial Glucose Response) 3 hours
Secondary iCmax of PPGR iCmax( maximal incremental value ) of PPGR (Postprandial Glucose Response) 3 hours
Secondary iAUC of PPIR Incremental area under the curve of PPIR (Postprandial Insulin Response) 1 hour, 2 hours
Secondary Tmax of PPIR Tmax(the time when Cmax is achieved) of PPIR (Postprandial Insulin Response) 3 hours
Secondary Cmax of PPIR Cmax(maximal value of measured timepoints) of PPIR (Postprandial Insulin Response) 3 hours
Secondary iCmax of PPIR iCmax( maximal incremental value ) of PPIR (Postprandial Insulin Response) 3 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1